top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Richard M. Traynor net worth and biography

Richard Traynor Biography and Net Worth

SVP of Certara

Rich Traynor serves as Certara’s General Counsel. Rich has been practicing law for over 20 years at publicly-traded and privately-held life sciences companies. Rich began his legal career in Dallas, Texas at the law firm of Jenkens & Gilchrist. In 2002, he moved back to his home state of New Jersey, where he became a partner at Porzio, Bromberg & Newman. In 2009, Rich joined LifeCell Corporation, where he became the Chief Legal and Compliance Officer. In that role, Rich served on the executive leadership team and was responsible for all legal and compliance matters, including licensing and acquisitions, buy- and sell-side contracting, dispute resolution, and enterprise risk assessment and mitigation. While at LifeCell, Rich also had responsibility for legal matters related to the commercial-side of LifeCell’s parent company, Acelity, in North and Latin America. Following a successful sale of the LifeCell business to Allergan, Rich joined Edge Therapeutics, a clinical stage biotechnology company, where he had broad responsibilities involving all legal matters impacting the Edge business, including negotiating complex commercial transactions, corporate governance, and developing corporate policies and procedures.

Rich graduated magna cum laude from the University of Notre Dame, where he earned a degree in the Program of Liberal Studies, and he received his law degree from the University of Virginia School of Law.

What is Richard M. Traynor's net worth?: The estimated net worth of Richard M. Traynor is at least $2.85 million as of April 1st, 2024. Mr. Traynor owns 173,524 shares of Certara stock worth more than $2,854,470 as of April 24th. This net worth approximation does not reflect any other investments that Mr. Traynor may own. Learn More about Richard M. Traynor's net worth.
How old is Richard M. Traynor?: Mr. Traynor is currently 52 years old. There are 4 older executives and no younger executives at Certara. The oldest executive at Certara is Mr. Leif E. Pedersen, President & Chief Commercial Officer, who is 59 years old. Learn More on Richard M. Traynor's age.
How do I contact Richard M. Traynor?: The corporate mailing address for Mr. Traynor and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Richard M. Traynor's contact information.
Has Richard M. Traynor been buying or selling shares of Certara?: In the last ninety days, Richard M. Traynor has sold $54,000.00 in Certara stock. Most recently, Richard M. Traynor sold 3,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a transaction totalling $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company's stock, valued at $3,123,432. Learn More on Richard M. Traynor's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, Certara insiders bought shares 1 times. They purchased a total of 193 shares worth more than $3,107.30. During the last year, insiders at the sold shares 7 times. They sold a total of 104,755 shares worth more than $1,776,756.55. The most recent insider tranaction occured on April, 2nd when insider Patrick F Smith sold 14,427 shares worth more than $243,094.95. Insiders at Certara own 2.6% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 4/2/2024.

Richard M. Traynor Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2024	Sell	3,000	$18.00	$54,000.00	173,524
2/12/2024	Sell	6,000	$18.00	$108,000.00	165,368
12/26/2023	Sell	6,000	$18.00	$108,000.00	171,368
5/11/2023	Sell	5,000	$20.82	$104,100.00	177,368
4/14/2023	Sell	5,000	$23.66	$118,300.00	182,368
3/16/2022	Sell	3,000	$20.00	$60,000.00
1/26/2022	Sell	3,000	$26.01	$78,030.00
1/18/2022	Sell	5,000	$27.44	$137,200.00
12/27/2021	Sell	3,000	$29.30	$87,900.00
11/15/2021	Sell	73,000	$37.98	$2,772,540.00
10/26/2021	Sell	3,000	$39.95	$119,850.00
10/15/2021	Sell	5,000	$37.38	$186,900.00
7/26/2021	Sell	3,000	$26.27	$78,810.00
6/28/2021	Sell	3,000	$28.38	$85,140.00	350,287
6/24/2021	Sell	5,000	$26.37	$131,850.00	353,287

Richard M. Traynor Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $16.45

$16.32

$16.74

50 Day Range

MA: $17.76

$15.93

$19.45

2 Week Range

Now: $16.45

$11.81

$24.70

Volume

421,449 shs

Average Volume

538,256 shs

Market Capitalization

$2.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad